Clinical trials: mRNA Vaccination
COVID-19 Pandemic
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety…
- Trial name
- NCT05305300
- Testing
- PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A, PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
- Where
- United Arab Emirates
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Cancer, Immune Checkpoint Inhibitors
COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival
COVICI-SURV is a nationwide, retrospective observational cohort study using the French national health data system (SNDS) to evaluate whether COVID-19 vaccination, particularly mRNA vaccination, received within 100 days before or…
- Conditions
- Cancer, Immune Checkpoint Inhibitors, COVID-19 Vaccination, Survival
- Trial name
- COVICI-SURV (NCT07729241)
- Where
- France
- Volunteers
- 95,015 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Influenza, COVID-19
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
- Trial name
- NCT06020118
- Testing
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
- Where
- 8 sites in United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Duke University
Melanoma
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I dose escalation is performed and the primary objective is the safety of different doses of TLR-DC and Trimix DC.
- Trial name
- NCT01530698
- Testing
- autologous dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Radboud University Medical Center
SARS-CoV-2
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation…
- Trial name
- NCT05894525
- Where
- Japan
- Volunteers
- 8,844 people
- Sponsor
- ModernaTX, Inc.
Cancer
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
- Trial name
- I-SPARC (NCT05075538)
- Testing
- Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1
- Where
- 2 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- Jules Bordet Institute
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Myocardial Injury, Vaccine Adverse Reaction
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.
- Conditions
- Myocardial Injury, Vaccine Adverse Reaction, COVID-19
- Trial name
- NCT05308680
- Testing
- BNT162b2
- Where
- Israel
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
COVID-19, Adult
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)
This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.
- Conditions
- COVID-19, Adult, Immunocompromised Patients
- Trial name
- NCT05597761
- Where
- 3 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Oliver Cornely, MD
COVID-19, SARS-CoV-2
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05260437
- Testing
- CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg)
- Where
- 24 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Core Body Temperature in Healthy Subjects, Immune Response to mRNA COVID-19 Vaccination
Fever Tracking Study
The aim of this study is to investigate the feasibility of continuous fever tracking of participants having fever symptoms in a home setting, using a core body temperature (CBT) sensor.
- Trial name
- NCT05475067
- Where
- Switzerland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
SARS-CoV-2
Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older
This is a multi-center, randomized, blinded, placebo-controlled, phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 bivalent mRNA vaccine (LVRNA021) as booster in participants aged 18 years…
- Trial name
- NCT05812014
- Testing
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution
- Where
- Pakistan
- Volunteers
- 9,800 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Myopericarditis, Myocarditis
Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old
Myopericarditis is a rare complication to messenger ribonucleic acid (mRNA) COVID-19 vaccines, especially in male adolescents and young adults. The risk in children 5-11 years old is unknown.
- Conditions
- Myopericarditis, Myocarditis, Vaccination; Complications, COVID-19 Pandemic
- Trial name
- NCT05186571
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccination
- Where
- Denmark
- Volunteers
- 350,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19
COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses.
- Trial name
- COVAXID (NCT04780659)
- Testing
- Comirnaty (COVID-19, mRNA vaccine)
- Where
- Sweden
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Ebola Virus Disease, COVID-19
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases.
- Trial name
- NCT06587503
- Testing
- BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Stage 4 NSCLC
Universal Immunization to Fortify Immunotherapy Efficacy and Response
Although immune checkpoint inhibitors (ICIs) have substantially extended survival in many patients, most patients do not achieve durable responses on these treatments.
- Trial name
- UNIFIER (NCT07597070)
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccine
- Volunteers
- 500 people
- Sponsor
- University of Florida
COVID-19 Pandemic
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
This is a randomized, double-blinded, placebo-controlled, dose-escalation study to valuate the safety and immunogenicity of RH109 as booster at 2 dose levels for ealthy adults who have received homologous or heterologous…
- Trial name
- NCT05609045
- Testing
- Lyophilized COVID-19 mRNA Vaccine, Sodium chloride
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wuhan Rhegen Biotechnology Co., Ltd.
Birth Outcomes, Safety
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart).
- Conditions
- Birth Outcomes, Safety, Adverse Event Following Immunization
- Trial name
- NCT06503900
- Testing
- mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
- Where
- 6 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have…
- Trial name
- NCT05636319
- Testing
- ABO1020
- Where
- 25 sites in Indonesia, Pakistan and 2 more
- Volunteers
- 14,168 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.